A method for preventing and treating back pain including discogenic back pain, which includes administering a mixed cell composition containing mammalian connective tissue cells and mammalian cells expressing TGF-β1 into the intervertebral disc defect site.

A method for preventing and treating back pain including discogenic back pain, which includes administering a mixed cell composition containing mammalian connective tissue cells and mammalian cells expressing TGF-β1 into the intervertebral disc defect site.

The present invention provides a device for adipose tissue processing, microfragmentation and facilitation of mechanical separation of adipose derived stem cells (“ADSCs”), methods of using the device to generate a stromal vascular fraction (“SVF”) and methods of the SVF.

The present invention provides a device for adipose tissue processing, microfragmentation and facilitation of mechanical separation of adipose derived stem cells (“ADSCs”), methods of using the device to generate a stromal vascular fraction (“SVF”) and methods of the SVF.

Disclosed are a cell-free fat extract and a preparation method therefor and the method of use thereof. The cell-free fat extract is used for preparing a composition or a preparation, wherein the composition or preparation is used in a method of: preventing and/or treating acute respiratory distress syndrome and/or acute lung injury, preventing and/or treating hypoxemia, improving pulmonary tissue inflammations, improving pulmonary tissue injuries, preventing and/or treating systemic inflammatory response syndrome, and preventing and/or treating multiple organ failure.

Disclosed are a cell-free fat extract and a preparation method therefor and the method of use thereof. The cell-free fat extract is used for preparing a composition or a preparation, wherein the composition or preparation is used in a method of: preventing and/or treating acute respiratory distress syndrome and/or acute lung injury, preventing and/or treating hypoxemia, improving pulmonary tissue inflammations, improving pulmonary tissue injuries, preventing and/or treating systemic inflammatory response syndrome, and preventing and/or treating multiple organ failure.

The present disclosure provides an in vitro method for preparation of human pluripotent stem cells (HPSCs) from human adipocyte-derived stem cells (ADSCs) without any genetic engineering techniques and without involving any exogenous gene elements, plasmid or transcription factors and the so obtained HPSCs are referred to as directly-generated human pluripotent stem cells (dgHPSCs). The present invention further provides an in vitro method for insulin production from the dgHPSCs by means of single- or co-transduction with human estrogen-related receptor gamma (ERRγ) gene by the lentivirus vector pWPI/ERRγ encoding the human ERRγ gene and/or with human insulin (INS) gene by a lentivirus vector, pWPI/INS encoding the human INS gene, where the insulin secreted by such co-transduced cells is higher than singly transduced cells. The present invention also provides an in vitro method for insulin production in a glucose-concentration responsive manner involving single transduction of the dgHPSCs with the human ERRγ gene.

The disclosure relates to populations of educated macrophages and monocytes generated ex vivo or in vivo, and methods of making and using the same using lipid A aminoalkylglucosaminide phosphate molecules, such as CRX molecules or extracellular vesicles (EVs) from mesenchymal stromal cells (MSC) stimulated with CRX molecules. Also described are EVs and methods for making and using the same from MSCs exposed to CRX.

The disclosure relates to populations of educated macrophages and monocytes generated ex vivo or in vivo, and methods of making and using the same using lipid A aminoalkylglucosaminide phosphate molecules, such as CRX molecules or extracellular vesicles (EVs) from mesenchymal stromal cells (MSC) stimulated with CRX molecules. Also described are EVs and methods for making and using the same from MSCs exposed to CRX.

The present disclosure relates to a pharmaceutical composition for preventing or treating a brain disease, comprising a stem cell-derived exosome surface-modified with a compound capable of binding to dopamine receptors or L-amino acid transporters as an active ingredient. The stem cell-derived exosome according to the present disclosure selectively binds to dopamine receptors (D2) overexpressed as autoreceptors in dopaminergic neurons in the substantia nigra through surface modification. Thereby, local accumulation in dopaminergic neurons is possible. In addition, it was identified that the stem cell-derived exosome exhibited an excellent neuron protective effect and neuron death inhibitory effect. Accordingly, the surface-modified stem cell-derived exosome according to the present disclosure is expected to be usefully used as a composition for preventing or treating a brain disease including Parkinson's disease and Alzheimer's disease.